摘要
目的探索达格列净片临床使用的安全性。方法总结上海交通大学附属第一人民医院2018年11月收治的2例使用达格列净片后出现酮症酸中毒的患者病例,并查阅国内外相关文献。结果2例糖尿病患者分别于服用达格列净片后第6日、第1日开始无明显诱因出现纳差、恶心、呕吐等症状,服药后第7日、第6日辅助检查示酮症酸中毒,经停药、补液、小剂量胰岛素静脉滴注、纠正电解质紊乱等治疗后,症状均好转。结论达格列净可能导致酮症酸中毒,医务人员应引起重视,在高危人群中使用该类药物应慎重。
Objective To explore the safety of dapagliflozin tablets in clinical application.Methods This article summarizes two cases which have been diagnosed with ketoacidosis after using dapagliflozin tablets from Shanghai General Hospital in November 2018.In addition,relevant literatures at home and abroad are reviewed.Results The two diabetic patients began to show symptoms of tolerance,nausea and vomiting without obvious inducement on the 6th and 1st day after taking dapagliflozin tablets respectively.On the 7th and 6th day after taking the tablets,they were diagnosed with ketoacidosis through laboratory examination.Their symptoms improved after drug withdrawal,fluid rehydration,low-dose insulin intravenous drip,electrolyte correction and other treatments.Conclusion Dapagliflozin tablets may cause ketoacidosis.Medical personnel should pay attention and use carefully in high-risk groups.
作者
袁梦瑚
钱凤丹
YUAN Menghu;QIAN Fengdan(Department of Clinical Pharmacy,Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200080,China;The First People's Hospital of Yichang,Yichang Hubei 443000,China;Institute of Pharmaceutic Preparation,China Three Gorges University,Yichang Hubei 443000,China)
出处
《中国药物警戒》
2020年第3期157-160,共4页
Chinese Journal of Pharmacovigilance
关键词
达格列净片
钠-葡萄糖协同转运蛋白2抑制剂
酮症酸中毒
糖尿病
dapaglif lozin tablets
sodium-dependent glucose transporters 2(SGLT-2)inhibitor
ketoacidosis
diabetes mellitus
